Basimglurant

Phase 1Small molecule

Roche

Basimglurant is one of 66 small molecule programs targeting Trigeminal Neuralgia. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Trigeminal NeuralgiaActive, not recruiting

Major Depressive DisorderActive, not recruiting

Trigeminal NeuralgiaPhase 2/Phase 3

Active, not recruiting

Major Depressive DisorderPhase 1

Active, not recruiting

Competition

Competitive Landscape

386 competitors in Major Depressive Disorder

#DrugCompanyPhaseTrials

Seroquel

EEngelhard Arzneimittel GmbH & Co.KG

Phase 3

12 2

Elavil

AstraZeneca

Phase 3

2 3

Daliresp

AstraZeneca

Phase 3

1 4

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 3

5 5

Nuplazid

AACADIA Pharmaceuticals Inc.

Phase 3

4 6

Latuda

SSunovion Respiratory Development Inc.

Phase 3

3 7

Ketalar

Boehringer Ingelheim

Phase 3

3 8

Celebrex

PPhiladelphia Eye Associates

Phase 3

2 9

Versed

CConrado Roberto Hoffmann Filho

Phase 3

2 10

Risperdal

WWim Janssens

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2/3Active, not recruiting

Trigeminal Neuralgia

NCT05217628

Clinical

Trials by Indication[1]

Major Depressive Disorder1 trial

A Study of the Safety, Tolerability, and Pharmacokinetics of Multiple-Ascending Dose Basimglurant in Healthy Subjects and in Patients With Major Depressive Disorder (MDD)

Completed· Roche logo

Roche·Phase 1·NCT02433093·56 enrolled

Trigeminal Neuralgia1 trial

An Efficacy and Safety Study of Basimglurant (NOE-101) in Patients With Trigeminal Neuralgia.

Active, not recruiting·NNoema Pharma AG·Phase 2/3·NCT05217628·166 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Basimglurant. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Basimglurant compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Basimglurant. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Roche company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Roche

Basimglurant

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Major Depressive Disorder1 trial

Trigeminal Neuralgia1 trial

References

Drug Info

Quick Facts

Related News